Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

SYNCHRONIZE-CVOT

PharmaDeviceNews SYNCHRONIZE-CVOT

Representative image: Eplontersen’s Phase 3 CARDIO-TTRansform setback raises questions about AstraZeneca and Ionis Pharmaceuticals’ ATTR cardiomyopathy strategy.

Pharma & Biotech

What Boehringer’s survodutide cardiovascular trial means for obesity approval

by Pallavi Madhiraju
November 10, 2026
0 Comments

Survodutide met its Phase 3 cardiovascular safety goal, but GI discontinuation near 20% could shape Boehringer’s obesity launch strategy.

Read More

Latest news and features

What Boehringer’s survodutide cardiovascular trial means for obesity approval
PIKTOR controlled disease in 83% of patients, so why did Faeth Therapeutics stock crash 42%?
Johnson & Johnson cut PSA by at least 50% in 73% of heavily treated patients. Can two bispecifics crack prostate cancer?
BIMZELX beat AbbVie’s US$5.8bn-a-quarter SKYRIZI on joint response. Why UCB still cannot claim broad superiority
Sapphiros and binx health combine as Onvaro around 1,000-device diagnostics network
Amsoki-cel produced responses in two-thirds of advanced melanoma patients. Can Obsidian make TIL therapy easier to deliver?
Lilly’s retatrutide cut knee pain as weight fell nearly 29%, but the Phase 3 result raises a bigger osteoarthritis question
Innovent’s Sintbilo cuts LDL by up to 65% as it targets first-line monotherapy label
Can Johnson & Johnson’s oral Icotyde compete with biologics in psoriatic arthritis?
Cesalatamig controlled disease in 90% at its chosen dose. Is OncoC4 ready for a pivotal NSCLC test?
Novartis lowered a major inherited heart-risk marker by 78%. Why did patients not benefit?
Rybrevant Faspro shrank tumours in 42% of heavily treated head and neck cancer patients. Can Phase 3 confirm the benefit?

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration US Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.